Gamma delta T-cell receptor (γδ TCR) (γδ TCR)

The Gamma delta T-cell receptor (γδ TCR) is a multi-subunit protein complex found on the surface of γδ T-cells, a specialized subset of lymphocytes that bridge innate and adaptive immunity [1]. Unlike the more common αβ TCR, the γδ TCR recognizes antigens in an MHC-independent manner, often responding to non-peptide phosphoantigens or stress-induced molecules such as Butyrophilin 3A1 (BTN3A1) and MICA/B [2]. In the context of hematologic malignancies, the γδ TCR (specifically the Vγ9Vδ2 subtype) senses cellular stress signals and metabolic changes characteristic of malignant transformation [3]. This recognition triggers potent cytotoxic responses, including the release of perforins, granzymes, and pro-inflammatory cytokines like IFN-γ and TNF-α [1]. Therapeutic interventions targeting this receptor include aminobisphosphonates, which cause the intracellular accumulation of phosphoantigens, and monoclonal or bispecific antibodies designed to activate γδ T-cells or recruit them to tumor cells [4][5]. These therapies are currently being explored in clinical trials for various leukemias and lymphomas due to their favorable safety profile and ability to target a broad range of tumors without the need for patient-specific HLA matching [6]. References: [1] Janeway's Immunobiology, 9th Ed. [2] Rigau et al. (2020) Science. [3] Hoeres et al. (2018) Cancer Immunol Immunother. [4] ImCheck Therapeutics (2024). [5] Lava Therapeutics (2024). [6] Sebestyen et al. (2020) Nat Rev Drug Discov.

Other names

Gamma-delta T-cell receptorT-cell receptor gamma/deltaVgamma9Vdelta2 TCRTCRG/TCRD complexT-cell receptor gamma chainT-cell receptor delta chain

Activation of γδ T-cells through the recognition of phosphoantigens or stress-induced ligands (e.g., BTN3A1), leading to MHC-independent cytotoxicity against malignant cells.